Arrowhead Pharmaceuticals released early Phase 1/2 data indicating its RNAi candidates produced meaningful fat‑loss signals when combined with GLP‑1/GIP receptor agonists in small cohorts. The company reported reductions in visceral and liver fat and additional weight loss versus GLP‑1 therapy alone in interim analyses, and said programs will progress into Phase 2 evaluation. Arrowhead framed the results as proof‑of‑concept for adipose‑directed siRNA delivery. The data are preliminary and limited in patient numbers; the company plans expanded cohorts and longer follow‑up to establish durability, safety and positioning alongside the growing class of incretin‑based medicines.